论文部分内容阅读
目的 :CD3AK细胞是由抗CD3单克隆抗体和IL 2共同激活诱导的肿瘤杀伤细胞。对 30例肿瘤患者自体CD3AK细胞及LAK细胞进行了比较性研究。方法 :采用MTT法检测CD3AK细胞及LAK细胞的杀瘤活性 ,应用流式细胞术进行免疫标志物分析。结果与结论 :肿瘤患者PBMNC诱导后产生的CD3AK细胞较LAK细胞有更强的增殖能力 ,但对Raji、K5 6 2细胞的生长抑制作用无明显区别 ;40 %～ 6 0 %CD3AK细胞表达CTL样表型 (CD3+ CD8+ ) ,约 40 %CD3AK细胞表达NK表型 (CD5 6 + )。同时亦观察到不同患者的免疫功能存在明显的个体差异。
OBJECTIVE: CD3AK cells are tumor killer cells induced by the co-activation of anti-CD3 monoclonal antibody and IL2. A comparative study of autologous CD3AK cells and LAK cells was performed in 30 patients with cancer. Methods: The cytotoxicity of CD3AK cells and LAK cells was detected by MTT assay. The immunological markers were analyzed by flow cytometry. RESULTS AND CONCLUSION: CD3AK cells induced by PBMNC in tumor patients had stronger proliferation ability than that of LAK cells, but there was no significant difference on the growth inhibition of Raji and K562 cells. CTL samples were expressed in 40% ~ 60% CD3AK cells Phenotype (CD3 + CD8 +), about 40% of CD3AK cells express the NK phenotype (CD5 6 +). At the same time, it is also observed that there are obvious individual differences in the immune function of different patients.